RxDoctor Payments Data

Yury Ragoza, DO

Family Medicine · Redmond, WANPI 1689054264

Payments from drug & device makers

$698in general payments, 2019–2025

Across 39 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$161
  • Pfizer$126
  • Novo Nordisk$89
  • Astellas Pharma US Inc$80
  • AstraZeneca$50
  • GSK$47
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$698 in reported general payments places this provider in the 80th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$89,408
Medicare patients
195
Services billed
1,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$197,458
JardianceEmpagliflozin84$85,056
EliquisApixaban68$71,979
MounjaroTirzepatide36$51,158
JanuviaSitagliptin Phosphate51$36,124
RybelsusSemaglutide17$24,933
TrulicityDulaglutide16$19,676
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,581
LinzessLinaclotide16$14,299
SymbicortBudesonide/Formoterol Fumarate46$12,280
EntrestoSacubitril/Valsartan13$8,764
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen224$8,649
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,222
MyrbetriqMirabegron11$6,028
Gabapentin288$5,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$89$222,392186 claims
PfizerEliquis, Premarin$126$75,52481 claims
Lilly USA, LLCMounjaro, Trulicity$27$70,83452 claims
GSKTrelegy Ellipta$47$18,58125 claims
AbbVieLinzess$161$14,29916 claims
AstraZenecaSymbicort$50$12,28046 claims
Astellas Pharma US IncMyrbetriq$80$6,02811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Redmond

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →